<DOC>
	<DOCNO>NCT02254005</DOCNO>
	<brief_summary>Maximum tolerate dose ( MTD ) , safety , pharmacokinetics , efficacy bivatuzumab mertansine</brief_summary>
	<brief_title>Single Dose Escalation Study Bivatuzumab Mertansine Female Patients With CD44v6 Positive Metastatic Breast Cancer</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Maytansine</mesh_term>
	<criteria>1. female patient age 18 year old 2. patient breast cancer positive CD44v6 least 50 % tumour cell 3. patient metastasis pretreated anthracyclines taxanes ( unless contraindication taxanes / anthracyclines ) amenable establish treatment 4. measurable tumour deposit one radiological technique ( MRI , CT ) 5. life expectancy least 6 month 6 . Eastern Cooperative Oncology Group ( ECOG ) performance score ≤ 2 7. patient must give write informed consent ( must consistent International Conference HarmonisationGood Clinical Practice ( ICHGCP ) local legislation ) 1. hypersensitivity humanise murine antibody , immunoconjugates excipients trial drug 2. know secondary malignancy require therapy 3. active infectious disease 4. brain metastasis require therapy 5. neuropathy common toxicity criterion ( CTC ) grade 2 6. absolute neutrophil count less 1,500/mm3 7. platelet count less 100,000/mm3 8. bilirubin great 1.5 mg/dl ( &gt; 26 μmol/L , système internationale ( SI ) unit equivalent ) 9. aspartate amino transferase ( AST ) and/or alanine amino transferase ( ALT ) great 3 time upper limit normal 10. serum creatinine great 1.5 mg/dl ( &gt; 132 μmol/L , SI unit equivalent ) 11. concomitant nononcological disease consider relevant evaluation safety trial drug 12. chemo immunotherapy within past four week prior treatment trial drug trial ( except present trial drug ) 13. radiotherapy breast thorax region within past four week inclusion trial 14. woman sexually active unwilling use medically acceptable method contraception 15. pregnancy lactation 16. treatment investigational drug participation another clinical trial within past four week start therapy concomitantly trial ( except present trial drug ) 17. patient unable comply protocol</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2014</verification_date>
</DOC>